AGS 009

Drug Profile

AGS 009

Alternative Names: AGS-009; NNC 0152-0000-0001

Latest Information Update: 18 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Argos Therapeutics Inc
  • Class Monoclonal antibodies
  • Mechanism of Action Interferon alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Systemic lupus erythematosus

Most Recent Events

  • 31 Dec 2013 Phase-I clinical trials in Systemic lupus erythematosus have been completed in USA (IV)
  • 07 Jun 2012 Adverse events, pharmacodynamics, and pharmacokinetics data from a phase Ia trial in Systemic lupus erythematosus presented at the 13th Annual Congress of the European League Against Rheumatism (EULAR-2012)
  • 01 Dec 2011 Argos Therapeutics completes a phase I trial in Systemic lupus erythematosus in USA (NCT00960362)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top